[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP3411068A4 - Protéines de liaison bispécifiques pour pd-l1 et kdr - Google Patents

Protéines de liaison bispécifiques pour pd-l1 et kdr Download PDF

Info

Publication number
EP3411068A4
EP3411068A4 EP17748163.7A EP17748163A EP3411068A4 EP 3411068 A4 EP3411068 A4 EP 3411068A4 EP 17748163 A EP17748163 A EP 17748163A EP 3411068 A4 EP3411068 A4 EP 3411068A4
Authority
EP
European Patent Office
Prior art keywords
kdr
binding proteins
bispecific binding
bispecific
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17748163.7A
Other languages
German (de)
English (en)
Other versions
EP3411068A2 (fr
Inventor
Zhenping Zhu
Dan Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kadmon Corp LLC
Original Assignee
Kadmon Corp LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp LLC filed Critical Kadmon Corp LLC
Publication of EP3411068A2 publication Critical patent/EP3411068A2/fr
Publication of EP3411068A4 publication Critical patent/EP3411068A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP17748163.7A 2016-02-02 2017-02-02 Protéines de liaison bispécifiques pour pd-l1 et kdr Withdrawn EP3411068A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662290350P 2016-02-02 2016-02-02
PCT/US2017/016230 WO2017136562A2 (fr) 2016-02-02 2017-02-02 Protéines de liaison bispécifiques pour pd-l1 et kdr

Publications (2)

Publication Number Publication Date
EP3411068A2 EP3411068A2 (fr) 2018-12-12
EP3411068A4 true EP3411068A4 (fr) 2020-01-29

Family

ID=59501012

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17748163.7A Withdrawn EP3411068A4 (fr) 2016-02-02 2017-02-02 Protéines de liaison bispécifiques pour pd-l1 et kdr

Country Status (5)

Country Link
EP (1) EP3411068A4 (fr)
JP (1) JP2019506863A (fr)
CN (1) CN109310755A (fr)
EA (1) EA201891732A1 (fr)
WO (1) WO2017136562A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268392A2 (fr) 2015-03-13 2018-01-17 CytomX Therapeutics, Inc. Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2018222949A1 (fr) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Anticorps anti-pdl1 activables, et leurs procédés d'utilisation
CN110799546B (zh) 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
CN111565738B (zh) * 2018-02-28 2023-12-26 圆祥生技股份有限公司 结合检查点阻碍物作为目标治疗的双功能性蛋白质
CN113302207A (zh) * 2018-11-16 2021-08-24 维尔托索宾科公司 Cd38和icam1抗体及其用途
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
US11407832B2 (en) 2018-12-03 2022-08-09 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant protein targeting PD-L1 and VEGF
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CA3144324A1 (fr) * 2019-06-24 2020-12-30 Novartis Ag Schema posologique et polytherapies pour des anticorps multispecifiques ciblant un antigene de maturation des lymphocytes b
WO2021026685A1 (fr) * 2019-08-09 2021-02-18 安徽瀚海博兴生物技术有限公司 Anticorps bispécifique anti-vegf-anti-pd1 ayant une structure d'un nouveau type
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体
CN113754772A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×kdr的双特异性抗体
CN114106190A (zh) * 2020-08-31 2022-03-01 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055996A2 (fr) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Inhibiteurs de rho kinase
WO2015109124A2 (fr) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Agents immunomodulateurs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051299A2 (fr) * 2003-11-19 2005-06-09 Dyax Corp. Proteines de liaison aux metalloproteinases
CA2657763C (fr) * 2006-08-03 2016-05-31 Vaccinex Inc. Anticorps monoclonaux anti-il-6 et leurs utilisations
US7935345B2 (en) * 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
RU2642318C2 (ru) * 2010-11-30 2018-01-24 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
KR101517320B1 (ko) * 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
EP3763741A1 (fr) * 2011-11-28 2021-01-13 Merck Patent GmbH Anticorps anti-pd-l1 et leurs utilisations
SG11201407859YA (en) * 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014055999A2 (fr) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Traitement de troubles oculaires
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055996A2 (fr) * 2012-10-05 2014-04-10 Kadmon Corporation, Llc Inhibiteurs de rho kinase
WO2015109124A2 (fr) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Agents immunomodulateurs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAN LU ET AL: "Abstract 572: A novel anti-PDL1 x anti-VEGFR2 bispecific antibody for enhanced antitumor immunity | Cancer Research", 16 April 2016 (2016-04-16), pages Abstract 572, XP055653955, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/76/14_Supplement/572.short> [retrieved on 20191218] *
ERIN LARKINS ET AL: "Regulatory Issues: FDA U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy", THE ONCOLOGIST, 2015, pages 1320 - 1325, XP055653942, Retrieved from the Internet <URL:http://theoncologist.alphamedpress.org/content/20/11/1320.long> [retrieved on 20191218] *
GEORGE W. SLEDGE: "Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?", JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 2, 10 January 2015 (2015-01-10), US, pages 133 - 135, XP055653932, ISSN: 0732-183X, DOI: 10.1200/JCO.2014.58.1298 *
ROLAND E. KONTERMANN ET AL: "Bispecific antibodies", DRUG DISCOVERY TODAY, vol. 20, no. 7, July 2015 (2015-07-01), AMSTERDAM, NL, pages 838 - 847, XP055251363, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2015.02.008 *

Also Published As

Publication number Publication date
EP3411068A2 (fr) 2018-12-12
JP2019506863A (ja) 2019-03-14
EA201891732A1 (ru) 2019-02-28
CN109310755A (zh) 2019-02-05
WO2017136562A2 (fr) 2017-08-10
WO2017136562A3 (fr) 2017-09-28

Similar Documents

Publication Publication Date Title
EP3411068A4 (fr) Protéines de liaison bispécifiques pour pd-l1 et kdr
IL283115A (en) Proteins that bind CD33 and CD3 bispecifically
EP3452089A4 (fr) Protéines de liaison bispécifiques et leurs utilisations
HK1252955A1 (zh) 針對程序性死亡配體(pd-l1)的單域抗體及其衍生蛋白
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
EP3489262A4 (fr) Protéines bispécifiques et leurs procédés de préparation
IL260846B (en) Antigen binding proteins that bind pd-l1
EP3370769A4 (fr) Anticorps se liant spécifiquement à tim-3 et leurs utilisations
EP3355920A4 (fr) Protéines de liaison à pd-1 et leurs méthodes d&#39;utilisation
EP3512549A4 (fr) Anticorps se liant à cd3
GB201805963D0 (en) PD-L1 Binding Affirmers and Uses Related Thereto
EP3471773A4 (fr) Anticorps se liant à cd3
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
EP3352760A4 (fr) Polypeptides de liaison à cd3
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3218483A4 (fr) Composés et procédés de modulation des protéines
EP3097122A4 (fr) Protéines de liaison et leurs procédés d&#39;utilisation
EP3140763A4 (fr) Système de prédiction d&#39;affinité de liaison et procédé associé
EP3244727A4 (fr) Protéines insecticides et leurs procédés d&#39;utilisation
EP3147298A4 (fr) Protéine de fusion pd-l1 et son utilisation
EP3302555A4 (fr) Procédés d&#39;utilisation de protéines de liaison cd3 et cd33 bispécifiques
EP3635100A4 (fr) Compositions et procédés pour exprimer l&#39;otoferline
EP3341021A4 (fr) Anticorps anti-alk et leurs procédés d&#39;utilisation
EP3307321A4 (fr) Plate-forme d&#39;anticorps multi-spécifiques et procédés associés
EP3256163A4 (fr) Méthodes et compositions pour moduler les protéines lilr

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180831

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/22 20060101ALI20191220BHEP

Ipc: A61K 39/395 20060101AFI20191220BHEP

Ipc: C07K 16/28 20060101ALI20191220BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200808